Search for: "Jim Beck"
Results 1 - 20
of 333
Sorted by Relevance
|
Sort by Date
5 Nov 2013, 8:42 am
Jim was appointed to the Programs Committee in September 2013 and will serve for one year. ### If you’d like more information on this topic, or to schedule an interview with Jim Beck, please call Vann Attorneys at (919) 510-8585 or email us at info@vannattorneys.com The post Jim Beck Selected and Appointed to YPN Programs Committee of Greater Raleigh Chamber of Commerce appeared first on Vann Attorneys | Attorneys at Law. [read post]
19 Jan 2010, 4:18 am
The Washington Legal Foundation has published a "legal backgrounder" piece by Sean Wajert, Jim Beck and Vincent Gallo (all of Dechert) titled "Reduced Legal Oversight for FDA Warning Letters Amplifies Compliance and Liability Risks. [read post]
5 Feb 2009, 3:22 pm
Today Mark Herrmann and Jim Beck have an excellent post replete with lots of good citations on why no-injury classes present insuperable class certification obstacles. [read post]
25 Aug 2009, 3:24 am
Expect this item to reduce embattled Fox TV personality Glenn Beck to tears--CNBC Mad Money host Jim Cramer thinks Beck is a "nice guy" and predicts that the mass exodus of advertisers who considered Beck radioactive after he called President Obama a racist (see "TUOL" post 8/24/09) will end and the sponsors will return to the fold.Of course, Cramer, a 54-year-old former hedge fund manager and co-founder of TheStreet.com, also predicted that… [read post]
10 Aug 2007, 9:08 am
Attorneys Jim Beck and Mark Hermann reply to the comment thread at this post critiquing their commentary on Abigail Alliance. [read post]
11 Feb 2015, 11:44 am
Read Jim Beck’s full post here. [read post]
9 Aug 2007, 10:08 am
Private attorneys Mark Hermann and Jim Beck have an extensive post at the Drug and Device Law blog discussing some of the practical implications of the Abigail Alliance litigation. [read post]
19 Jan 2010, 9:03 pm
Jim Beck recounts what happened when the inimitable jurist was presented with the case of Carr v. [read post]
29 Aug 2009, 4:44 am
Over at Drug & Device Law, Jim Beck writes about the Sixth Circuit's decision affirming summary judgment for Wyeth based on Tennessee's statute of repose. - SBS [read post]
30 Dec 2009, 9:51 am
Jim Beck at Drug and Device Law has an interesting post about choice of law issues in mass tort cases involving claims for punitive damages. [read post]
14 May 2019, 1:38 pm
It alleged that Beck, a former insurance company... [read post]
4 Jun 2007, 12:18 pm
Jim Beck and Mark Herrmann at the Drug and Device Law Blog have a wonderful post called Anatomy of a Mass Tort. [read post]
25 Jun 2012, 9:09 am
Presented by James Vann and Jim Beck Wednesday, June 20, 2012 [read post]
13 Oct 2008, 5:12 pm
If you want to keep up with what's happening in federal preemption jurisprudence, the best place is the Drug and Device Law blog of Jim Beck (Deckert LLP, Philadelphia) and Mark Herrmann (Jones Day, Chicago). [read post]
30 Oct 2007, 8:52 am
Always interesting to see what Jim Beck and Mark Herrmann have to say about pharmaceutical litigation (and for anyone who's looking for even more blogs that address mass torts, here's the... [read post]
15 Mar 2010, 8:39 pm
Jim Beck (Dechert, Philadelphia) has a short comment on his Drug and Device Law blog, "Might The First Amendment Become Moot? [read post]
15 Jan 2010, 4:02 pm
On his Drug and Device Law blog, Jim Beck (Dechert LLP, Philadelphia) slices and dices the government's motion to dismiss in Allergan’s First Amendment challenge to the FDA’s regulations on off-label promotion, "Beware The FDA Bearing Regulations: An Allergan Update".... [read post]
27 Feb 2007, 9:09 pm
And Beck and Herrmann do a comprehensive analysis of... [read post]
4 Aug 2009, 2:42 pm
Another interesting discussion from the Drug and Device Law blog of Jim Beck (Dechert LLP) and Mark Herrmann (Jones Day), "Compounding, Repackaging, or Manufacturing? [read post]
10 Mar 2009, 5:37 am
Our own Jim Copland and Paul Howard of the Manhattan Institute, in the Washington Times; Gordon Crovitz, in the Wall Street Journal. [read post]
